{"id":"W3089332307","doi":"10.1016/j.annonc.2020.08.890","title":"631P Darolutamide (D), enzalutamide (E) and apalutamide (A), the risk of adverse events (AEs) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC): Number needed to harm (NNH)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Janssen Research and Development; Genentech; Daiichi Sankyo Europe; Servier; Eisai; Astellas Pharma; Merck Sharp and Dohme; Cilag; Puma Biotechnology; Sierra Oncology; Pfizer; Incyte; Ipsen; Clovis Oncology; Astex Pharmaceuticals; Sanofi; Exelixis; Karyopharm Therapeutics; Teva Pharmaceutical Industries; Amgen; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Number needed to harm; Enzalutamide; Adverse effect; Rate ratio; Prostate cancer; Internal medicine; Relative risk; Confidence interval; Number needed to treat; Cancer; Androgen receptor","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001727547,0.0002111341,0.0006089244,0.0003329574,0.0001232771,0.0003625109,0.0001761507,0.0003890051,0.003034463],"category_scores_gemma":[0.003320594,0.0001210678,0.001394635,0.0003461001,0.0001769627,0.0003605106,0.0002615387,0.0008230617,0.0002860432],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005234181,"about_ca_system_score_gemma":0.0005005746,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008055745,"about_ca_topic_score_gemma":0.002767663,"domain_scores_codex":[0.9987121,0.0007246847,0.000115088,0.00006438975,0.0003120738,0.00007173092],"domain_scores_gemma":[0.9983911,0.0007474718,0.0005579517,0.00004770327,0.0001211805,0.0001346252],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.03732307,0.0006904459,0.1943047,0.003643278,0.008174244,0.0007206344,0.00008487427,0.003747903,0.005894767,0.001312279,0.008661255,0.7354426],"study_design_scores_gemma":[0.006979776,0.02539703,0.8750662,0.001649614,0.008462202,0.006811259,0.0003563461,0.01099992,0.007440881,0.008363559,0.04837525,0.00009791399],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8161212,0.1455828,0.004135258,0.00728594,0.0006963848,0.0002913284,0.002346704,0.0001884173,0.02335199],"genre_scores_gemma":[0.9849192,0.009779074,0.001409112,0.0007412325,0.0001031514,0.00005523398,0.0005097357,0.000009518848,0.002473584],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003034463,"threshold_uncertainty_score":0.01015133,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04392981010887884,"score_gpt":0.3677705877993503,"score_spread":0.3238407776904715,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}